Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.
Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.
复制标题
非诺贝特可有效减少高甘油三酯血症男性的残留和小密度低密度脂蛋白，并增加高密度脂蛋白颗粒数量 - 一项核磁共振研究。
DOI：
10.5551/jat.11.278
复制
发表时间：
2004
影响因子：
4.4
通讯作者：
S. Mochizuki
中科院分区：
文献类型：
--
作者：
K. Ikewaki;J. Tohyama;Yoshinobu Nakata;T. Wakikawa;T. Kido;S. Mochizuki
高甘油三酯血症通常与小而密的低密度脂蛋白(LDL)、残留物增加和高密度脂蛋白(HDL)-胆固醇(C)降低有关，这些都构成了血脂异常三联症。本研究的目的是探讨非诺贝特对高甘油三酯血症男性脂蛋白亚组分和炎症标志物的影响。20名高甘油三酯血症患者服用非诺贝特，每天200毫克，共8周。用核磁共振波谱测定脂蛋白亚类。同时检测C反应蛋白(CRP)、白介素6(IL-6)、单核细胞趋化蛋白-1(MCP-1)等炎症标志物。非诺贝特降低甘油三酯58%，升高高密度脂蛋白胆固醇18%。核磁共振分析显示，极低密度脂蛋白(VLDL)，尤其是大颗粒VLDL、中密度脂蛋白(IDL)和小颗粒低密度脂蛋白(Small-LDL)显著减少，且分布向大颗粒方向移动。高密度脂蛋白的分布发生改变；小高密度脂蛋白增多，大高密度脂蛋白减少，导致高密度脂蛋白颗粒尺寸显著减小，从9.1 nm降至8.9 nm，高密度脂蛋白颗粒数增加27%。炎症标志物中，CRP显著降低42%。总而言之，非诺贝特通过减少残留和小的低密度脂蛋白，以及增加高密度脂蛋白颗粒，有效地改善了致动脉粥样硬化性血脂异常。这些效应，加上对炎症的有利作用，可能会为高甘油三酯血症患者提供临床益处。
Hypertriglyceridemia is often associated with small dense low density lipoprotein (LDL), elevated remnants, and decreased high density lipoprotein (HDL)-cholesterol (C), which comprise the dyslipidemic triad. The objective of this study was to investigate the effect of fenofibrate on the lipoprotein subfraction profile and inflammation markers in hypertriglyceridemic men. Twenty hypertriglyceridemic men were administered fenofibrate, 200 mg daily, for 8 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6), and monocyte chemotactic protein-1 (MCP-1) were also determined. Fenofibrate lowered triglyceride (TG) by 58% and increased HDL-C by 18%. NMR analysis revealed that very low density lipoprotein (VLDL), particularly large VLDL, intermediate density lipoprotein (IDL), and small LDL, were significantly decreased, and LDL distribution shifted towards the larger particles. HDL distribution was altered; there was an increase in small HDL and a decrease in large HDL, resulting in a significant decrease in HDL particle size, from 9.1 to 8.9 nm, as well as a 27% increase in HDL particle number. Among inflammation markers, CRP was significantly decreased by 42%. In conclusion, fenofibrate effectively improves atherogenic dyslipidemia by reducing remnants and small LDL, as well as by increasing HDL particles. These effects, together with the favorable effect on inflammation, might provide a clinical benefit in hypertriglyceridemic subjects.
登录
查看更多内容
DOI：
10.1001/jama.1988.03410130125037
发表时间：
1988-10
期刊：
JAMA
影响因子：
--
作者：
M. Austin;J. Breslow;C. Hennekens;Julie E. Buring;W. Willett;R. Krauss
通讯作者：
M. Austin;J. Breslow;C. Hennekens;Julie E. Buring;W. Willett;R. Krauss
影响因子：
0.7
作者：
J. Otvos
通讯作者：
J. Otvos
影响因子：
8.7
作者：
Freedman, DS;Otvos, JD;Walker, JA
通讯作者：
Walker, JA
影响因子：
9.3
作者：
N. Rifai;R. Tracy;P. Ridker
通讯作者：
N. Rifai;R. Tracy;P. Ridker
脱辅基蛋白 E 表型的简化等电聚焦/免疫印迹测定。
影响因子：
9.3
作者：
Kataoka,S;Paidi,M;Howard,BV
通讯作者：
Howard,BV